abiraterone acetate and prednisolone


( Last Updated : June 6, 2022)
Generic Name:
abiraterone acetate and prednisolone
Project Status:
Active
Therapeutic Area:
High-risk non-metastatic prostate cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PC0291-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Indications:
​For the treatment of high-risk non-metastatic prostate cancer.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones

Call for patient/clinician input open06-Jun-22
Call for patient/clinician input closed29-Jul-22
Call For Industry Feedback Open06-Jun-22
Call For Industry Feedback Closed29-Jul-22
Review initiated 06-Jun-22
Expert Committee Meeting (Initial)12-Oct-22
Draft recommendation posted for stakeholder feedback27-Oct-22
End Of Feedback Period10-Nov-22